



A. VIRGINIA LIVOLSI, G. FADDA\*

Dept. of Anatomic Pathology and Laboratory Medicine  
University of Pennsylvania Medical Center  
Philadelphia (USA)

\*Istituto di Anatomia e Istologia Patologica  
Università Cattolica del Sacro Cuore - Roma

## *Lettura magistrale*

Certain philosophical and practical principles need to be accepted by endocrinologists, internists, surgeons and pathologists as we enter the 21<sup>st</sup> century. These include:

- The primary approach to a single or dominant nodule in the thyroid of a euthyroid patient is FNA.
- FNA can be diagnostic in papillary cancer, (including some examples of the follicular variant), medullary carcinoma and anaplastic carcinoma.
- If FNA is diagnostic, appropriate therapy should be undertaken *without* further diagnostic tests, i.e., total or near total thyroidectomy for papillary or medullary cancer. If clinician does not trust (enough to act upon) the cytodiagnosis, he/she should find a cytopathologist he/she can trust!
- Most thyroid nodules are follicular in pattern. In many cases, one can define nodular goiter on FNA due to colloid, etc., and this is reassuring to patient and clinician. If however, the nodule is follicular (or Hürthle cell) and cellularity and scant colloid, etc., a neoplasm is suspected, the cytologist cannot distinguish benign from malignant lesions in the two categories on FNA. FNA samples the center of the tumor and a diagnosis of malignancy is based on invasion at or beyond the level of the capsule. Hence, in these cases, the diagnosis must await histologic evaluation of the resected nodule.
- Because invasion is an encapsulated follicular or Hurthle cell tumor may be focal, generous sampling of the capsule is required to find it or its absence. In most pathology labs, sampling the whole or even one half the capsule of a follicular tumor is prohibitively expensive of technical and time resources. In addition, FNA artifacts (enhanced by artifacts of freezing) could lead to over-diagnosis.

- These then are our recommendations (and the surgeons who do the majority (95%) of thyroid surgeries at University of Pennsylvania Medical Center follow these):
  - a) If FNA is definitely diagnostic (e.g. papillary cancer) proceed with surgical procedure deemed appropriate for that diagnosis
  - b) If FNA diagnosis is follicular or Hurthle cell neoplasm, do not freeze:
    - sampling
    - post FNA artifact
    - Most (80-85%) are benign
  - c) If FNA diagnosis is follicular lesion, suspect follicular variant of papillary carcinoma - can freeze lesion and perform intraoperative cytology examination: if nuclei are perfect or/and if on frozen, sclerosis is seen - **you can make a definitive frozen section** bord diagnosis and surgery can proceed.
  - d) We will **always freeze tissue other than the primary intrathyroidal** nodule, e.g., lymph nodes, parathyroids for identification, etc.

## Reference

- 1) Bronner M.P., Hamilton R., LiVolsi V.A.: *Frozen section analysis of thyroid follicular lesions*. Endocrine Pathol, 5:154-151, 1994.
- 2) Irish, J.C., et al: *Accuracy of pathologic diagnosis in thyroid lesions*. Arch Otolaryngol Head Neck Surg, 118:918-922, 1992,
- 3) Crowe P.J., Chetty R., Dent D.M.: *Thyroid frozen section: flawed but helpful*. Aust N-Z J I Surgery, 63:275-278, 1993.
- 4) Rodriguez J.M. et al: *Comparison between preoperative cytology and intraoperative frozen section biopsy in the diagnosis of thyroid nodules*. Brit J Surg, 81:1151-1154, 1994.
- 5) Montone K.T., LiVolsi V.A.: *Frozen section analysis of thyroidectomy specimens: Experience over a 12 year period*. Path. Case Rev. 2:241-245, 1997.

## Epidemiology and Natural History of Differentiated Thyroid Cancer

If one examines epidemiologic factors in the development of thyroid cancer, differences between follicular and papillary cancer appear.  
Follicular Carcinoma:

Iodine Deficiency  
Cytogenetic changes: 3p-  
Papillary Carcinoma:  
Radiation  
Genetic  
Iodine Excess  
? Thyroiditis

The Natural History of Differentiated Thyroid Cancer depends on whether the lesion is papillary or follicular. If the latter, differences exist between minimally invasive versus angioinvasive lesions.

Papillary carcinoma (usual type - over 80%) is characterized by:

Lymphatic invasion  
Lymph node metastases  
"Multifocality"  
Long natural history  
Rare and late distant metastases (Lung)

Follicular carcinoma if minimally invasive (capsule of tumor only; no vascular invasion) is probably extremely benign (90% survival at 10 years or better); however, good data are not available.

Angioinvasive encapsulated follicular carcinomas have a 30-50% metastatic rate at 10 years (to lung, bone, brain). There appears to be a correlation between number of vessels invaded and prognosis. These are real cancers and need to be treated aggressively.

## References

- 1) LiVolsi V.A.: *Papillary neoplasms of the thyroid. Pathologic and prognostic features* Am J Clin Pathol, 97:426-434, 1992.
- 2) Hay I.D.: *Papillary thyroid carcinoma*. Endocrinol Metab Clin North Am, 19:545-576, 1990.
- 3) Mazzaferri E.L., Jhiang S.: *Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer*. Am J Med, 97:418-428, 1994.
- 4) Gaertner E.M., Davidson M., Wenig B.: *The columnar cell variant of thyroid papillary carcinoma*. Am J Surg Pathol, 19:940-047, 1995.
- 5) Carcangiu M.L., Bianchi S.: *Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases*. Am J Surg Pathol, 13:1041-1049, 1989.
- 6) Nikiforov Y., Gnepp D.R.: *Pediatric thyroid cancer after the Chernobyl disaster: Pathomorphological study of 84 cases from the Republic of Belarus*. Cancer, 74:748-766, 1994.
- 7) Carcangiu M.L., et al: *Papillary carcinoma of the thyroid. A clinicopathologic study of 244 cases treated at the University of Florence, Italy*. Cancer 55:805-828, 1985.
- 8) Carcangiu M.L., et al.: *Papillary thyroid carcinoma. A study of its many morphologic expressions and clinical correlates*. Pathol Annu, 20(Pt 1):1-44, 1985.
- 9) Chen K.T.K., Rosai J.: *Follicular variant of thyroid papillary*

*carcinoma: A clinicopathologic study of six cases*. Am J Surg Pathol, 1:123, 1977.

10) Cohn K.H., et al: *Prognostic value of nuclear DNA content in papillary thyroid carcinoma*. World J Surg, 8:474-480, 1984.

11) Evans H.L.: *Columnar cell carcinoma of the thyroid. A report of two cases of an aggressive variant of thyroid carcinoma*. Am J Clin Pathol, 85:77-80, 1986.

12) Favus M.J., et al: *Thyroid cancer occurring as a late consequence of head and neck irradiation*. N Engl J Med, 294:298, 1976.

13) Vickery A.L., et al: *Treatment of intrathyroidal papillary carcinoma of the thyroid*. Cancer 60:2587-2595, 1987.

14) Robison, L.L., Mertens A.: *Second tumors after treatment of childhood malignancies*. Hematol Oncol NA, 7:401-415, 1993.

15) LiVolsi V.A.: *Review Article: "Papillary Neoplasms of the Thyroid: Pathologic and Prognostic Features."* Am J Clin Pathol 97:426-434, 1992.

16) Ain K.B.: *Papillary thyroid carcinoma. Etiology, Assessment and Therapy*. Endocrinol Metab Clin NA, 24:711-760, 1995 (Excellent up to date review).

17) Harach H.R. et al: *Thyroid carcinoma and thyroiditis in an endemic goiter region before and after iodine prophylaxis*. Acta Endocrinol, 108:55-60, 1985.

18) Harach H.R., et al: *Factor VIII as a marker of endothelial cell in follicular carcinoma of the thyroid*. J Clin Pathol, 36:1050-1054, 1977.

19) Joensuu H., et al: *DNA aneuploidy in follicular adenomas of the thyroid gland*. Pathol, 124:373-376, 1987.

20) Kahn N., Perzin K.H.: *Follicular carcinoma of the thyroid: An evaluation of the histologic criteria used for diagnosis*. Pathol Annu 18 (Part 1):221-253, 1983.

21) Kendall C.H., et al: *Follicular thyroid tumors. A study of laminin and type IV collagen in basement membrane and endothelium*. J Clin Pathol, 38:1 100-1105, 1995.

22) Lang W., et al: *Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14 year period with emphasis on morphological finds*. Am J Surg Pathol, 10:246-255, 1986.

23) Lang W., et al: *The differentiation of atypical adenomas and encapsulated follicular carcinomas in the thyroid gland*. Virch Arch Pathol Anat, 385:125-141, 1980.

## Prognostic Factors in Differentiated Thyroid Cancer

In general, many large series have shown that age, size of tumor, sex and extrathyroidal extension (ETE) are correlated with prognosis. Hence, older age, large size, male sex and ETE are bad.

Recently, at least for papillary cancer subtype (as defined by histology) may correlate with prognosis: hence tall cell variant, columnar cell variant and diffuse sclerosing type are aggressive tumors.

Other histologic parameters which may affect prognosis include: lymphoid reaction to tumor, vascular invasion

and “dedifferentiated areas.” More studies are needed to test validity of these features.

For follicular carcinoma, number of vessels invaded appears to correlate with prognosis. “Dedifferentiated” foci, spontaneous necrosis and easily found mitoses also may portend aggressive behavior.

Recent studies have shown other parameters may influence prognosis: DNA ploidy (S-phase confusing results), ret/PTC (conflicting results), p53 mutations (very rarely seen in differentiated thyroid cancers).

Immunostains for CEA, LeuM, Leu7, S 100, and EMA have been valued by some authors and debunked by others.

## References

- 1) Kahn N., Perzin K.H.: *Follicular carcinoma of the thyroid: An evaluation of the histologic criteria used for diagnosis*. Pathol Annu, 18 (Part 1):221-253, 1983.
- 2) Lang, W., et al: *Risk factors in follicular thyroid carcinomas. A retrospective follow up study covering a 14 year period with emphasis on morphological findings*.
- 3) Crile G. et al: *Factors influencing the survival of patients with follicular carcinoma of the thyroid gland*. Surg Gynecol Obstet, 160:409-412, 1985.
- 4) Evans H.L.: *Follicular neoplasm of the thyroid*. Cancer, 54:535-540, 1984.
- 5) Franssila K.O. et al: *Follicular carcinoma*. Sem Diagn Pathol, 2:101-122, 1985.
- 6) Schroder S., et al.: *The encapsulated follicular carcinoma of the thyroid*. Virch Arch Pathol Anat, 402:259-273, 1984.
- 7) Yamashina M.: *Follicular neoplasms of the thyroid*. Am J Surg Pathol, 16:392-400, 1992.
- 8) Mazzaferri E., Jhiang S.: *Long term follow up impact of initial therapy on papillary and follicular thyroid cancer*. Am J Med, 97:418-428, 1994.
- 9) LiVolsi, VA: *Review Article: “Papillary Neoplasms of the Thyroid: Pathologic and Prognostic Features.”* Am J Clin Pathol, 97:426-434, 1992.
- 10) Ain K.B.: *Papillary thyroid carcinoma. Etiology, Assessment and Therapy*. Endocrinol Metab Clin NA, 24:711-760, 1995 (Excellent up to date review).
- 11) Vickery A.L., et al: *Treatment of intrathyroidal papillary carcinoma of the thyroid*. Cancer 60:2587-2595, 1987.
- 12) Tscholl-Ducommun J., Hedinger C.: *Papillary thyroid carcinoma. Morphology and prognosis*. Virch Arch Anat Pathol, 396:19-39, 1982.
- 13) Evans H.L.: *Encapsulated papillary neoplasms of the thyroid. A study of 14 cases followed for a minimum of 10 years*. Am J Surg Pathol, 11:592-597, 1987.
- 14) Carcangiu M.L., et al: *Papillary thyroid carcinoma. A study of its many morphologic expressions and clinical correlates*. Pathol Annu, 20 (Pt I): 1-44, 1985.
- 15) Bocker W., et al: *Minimal thyroid neoplasia*. Rec Results Cancer Res, 106:131-138, 1988.
- 16) McConahey W.M.. et al: *Papillary thyroid cancer treated at the Mayo Clinic, 1946 Through 1970: initial manifestations, pathologic findings, therapy and outcome*. Mayo Clin Proc, 61:978-996, 1986.
- 17) Samaan N.A., et al.: *Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases*. J Clin Endocrinol Metab, 56, 1131-1138. 1983.
- 18) Schroder S., et al: *Dendritic/Langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow up data*. Am J Clin Pathol, 89:295-300, 1988.
- 19) Johannessen J.V., et al.: *A flow cytometric DNA analysis of papillary thyroid carcinoma*. Lab Invest, 45:336, 1981.

